OR WAIT null SECS
The ability to deal with the complexity of the clinical supply process has shifted the balance of power to clinical supply chain specialists.
In late February of this year, the US Food and Drug Administration released its Draft Guidance for Industry on Adaptive Design Clinical Trials for Drugs and Biologics. Unlike traditional clinical studies, which require that the elements of the protocol are immutable throughout the study, adaptive trials can include elements that can be changed mid-trial, so long as the conditions under which changes are made and the nature of those changes are established in the study design.
Adaptive trials promise to lower trial costs and speed up the development process by reducing the number of trials that must be conducted and increasing the probability that a trial will reach the desired endpoint. They are indicative of the growing complexity of clinical research as bio/pharmaceutical companies respond to the growing concern over the cost and safety of new drugs. Companies must confront an expanding range of challenges when developing and testing new drug candidates. Some of those challenges include:
These challenges have increased the complexity of clinical trials. Examples of this increased complexity include the expanding number of clinical trials in which new drug candidates are tested against active controls (approved, marketed drugs); clinical trial designs incorporating more arms (patient sub-groups); adaptive trials; and the growing number of sites per study.
The increased complexity of clinical trials is posing new challenges across the supply chain.
Packaging complexity: large multi-arm studies greatly increase the number of packaging configurations needed to conduct a trial. A study with at least one active control, one placebo, and a development candidate can easily have six or more packaging configurations, depending on the protocol. If the study is being conducted in multiple countries, labeling the packages to incorporate multiple languages is an additional challenge.
Forecasting complexity: large multi-country studies make clinical supply forecasting very difficult. For example, estimating how many kits will be required in each country means being able to forecast enrollment rates with some accuracy, which is extremely difficult. Adaptive trials further complicate the problem.
Logistical complexity: shipping clinical supplies to multiple countries raises problems such as transportation and storage under good manufacturing practice (GMP) conditions. Because of the growing number of biologics, maintenance of temperature conditions across the supply chain, i.e., cold chain management, has become a major concern.
The growing complexity of clinical trials and the clinical supply chain has opened up an "arms race" in the clinical supply chain industry because participants are competing to offer the most sophisticated capabilities. For instance, clinical packagers are investing millions in information systems that can track individual packages from the warehouse shelf through every step in the supply chain, all the way to the clinic or physician's office where the patient receives his drug supply.
In addition, supply chain complexity has boosted the importance of a range of specialty providers and services across the supply chain. Some examples are below.
The ability to deal with the complexity of the clinical supply process has shifted the balance of power in the clinical supply chain to CROs, especially the major clinical packagers and logistics services providers. Being able to handle clinical supply chain complexity requires major investments in information technology and specialized packaging and labeling equipment. It also rewards companies with the know-how to devise sophisticated solutions for complex supply chain problems and the experience to accurately and safely implement those sophisticated solutions.
Only companies that handle hundreds of clinical supply projects annually can use the experience to devise and implement those sophisticated solutions and afford to make the necessary investments. There is no way that bio/pharmaceutical companies can hope to match those capabilities in their in-house clinical supply operations.
Jim Miller is president of PharmSource Information Services, Inc. , Springfield, VA, 703.383.4903,email@example.com